Bile Duct Cancer

This is a type of cancer that starts in the bile ducts, which are tubes that carry bile from the liver to the gallbladder. It's a serious condition that needs medical treatment.

Condition

What people with Bile Duct Cancer report

Every report comes from a Lived member, sent anonymously.

Have you tried Gemcitabine for Bile Duct Cancer?

NameHow it went

About Bile Duct Cancer

What It Is

Bile duct cancer, also called cholangiocarcinoma, is a rare cancer that starts in the lining of the bile ducts. These are the tubes that carry bile, a digestive fluid made by the liver, through the liver and gallbladder and into the small intestine. When a tumor narrows or blocks a duct, bile backs up, which is why the first sign is often jaundice: yellowing of the skin and the whites of the eyes, frequently with itching, dark urine and pale stools. Doctors group bile duct cancer by where it starts, because location shapes both symptoms and treatment. Intrahepatic cancer begins in the small ducts inside the liver and may cause few symptoms until it is large. Extrahepatic cancer begins outside the liver, either where the main ducts leave the liver (perihilar, sometimes called a Klatskin tumor) or lower down, near the pancreas (distal). Bile duct cancer is related to gallbladder cancer, but they are different diseases. Because it rarely causes symptoms early and there is no routine screening test, bile duct cancer is often found after it has spread. That makes it a serious diagnosis, but treatment has changed meaningfully in recent years.

Causes & Risk Factors

Most bile duct cancers develop after years of inflammation or irritation in the bile ducts, although many people diagnosed have no known risk factor. The best-established risk factor is primary sclerosing cholangitis, a long-term disease in which inflammation scars and narrows the bile ducts; many people with it also have ulcerative colitis. Bile duct cysts present from birth (choledochal cysts), stones inside the liver's ducts, and cirrhosis or long-term hepatitis B or C infection also raise risk. Worldwide, the disease is far more common in parts of Southeast Asia and China, largely because of liver flukes, tiny parasites caught by eating raw or undercooked freshwater fish. Older age (most people are diagnosed in their 60s or 70s), obesity, diabetes and heavy alcohol use are also linked to higher risk. A few inherited conditions, such as Lynch syndrome, add risk too. Having one of these factors does not mean someone will develop this cancer, and for any one person it is usually not possible to say which factor, if any, caused the cancer.

How It's Diagnosed

Evaluation usually starts with jaundice or abnormal liver blood tests. A raised bilirubin (the yellow pigment that causes jaundice) or alkaline phosphatase level suggests that bile is not draining properly, but many conditions, including gallstones and hepatitis, can cause the same pattern. Blood tests for the tumor markers CA 19-9 and CEA (carcinoembryonic antigen), proteins that some cancers release into the blood, can support the diagnosis and are often followed during treatment. A high CA 19-9 alone does not prove cancer, and a normal level does not rule it out. Imaging shows where a duct is narrowed and whether the cancer has spread. Ultrasound is often first, followed by CT and MRI. A special MRI of the bile ducts called MRCP (magnetic resonance cholangiopancreatography) maps the ducts without an instrument. To get a tissue sample, doctors may use ERCP (endoscopic retrograde cholangiopancreatography), in which a flexible scope is passed through the mouth into the small intestine, or endoscopic ultrasound. ERCP can also place a stent to relieve a blockage at the same time. Bile duct cancers can be small and hard to sample, so a first biopsy is sometimes inconclusive. The central question of this workup is whether surgery can remove all of the cancer. For that reason, it helps to be assessed at a center experienced with bile duct cancer before any biopsy through the skin or major procedure. When the cancer is advanced, doctors also send the tumor for molecular (biomarker) testing, which looks for specific gene changes that some newer medicines target.

Treatment Options

Surgery to remove the tumor with a margin of healthy tissue is the only treatment that offers a realistic chance of cure. The operation depends on location: cancers inside the liver usually need removal of part of the liver, perihilar cancers often need removal of part of the liver and the duct junction, and distal cancers usually need a Whipple procedure, which removes the head of the pancreas, the gallbladder, part of the small intestine and the lower bile duct. These are major operations with a long recovery. Most people, however, cannot have their cancer completely removed, because it has spread, involves key blood vessels, or they are not well enough for surgery. A liver transplant is an option for a small group of carefully selected people with perihilar cancer, usually at specialized centers. After successful surgery, about six months of capecitabine, a chemotherapy pill, is recommended to lower the chance of the cancer returning. For cancers outside the liver, radiation combined with chemotherapy may be added when cancer cells are found at the edge of what was removed. For cancer that cannot be removed or has spread, the usual first treatment is chemotherapy with gemcitabine and cisplatin combined with an immunotherapy drug, durvalumab (Imfinzi) or pembrolizumab (Keytruda). These immunotherapy drugs help the immune system recognize cancer cells. In a large trial, adding immunotherapy extended median survival by about one to two months; some people respond much longer. Immunotherapy can sometimes make the immune system inflame healthy organs such as the bowel, liver, lungs or thyroid, which can be serious and needs prompt treatment. Some advanced bile duct cancers carry a gene change with a matching targeted drug, which is why tumor testing matters wherever in the bile ducts the cancer started. Each drug works only when testing finds its matching gene change. Pemigatinib (Pemazyre) and futibatinib (Lytgobi) target FGFR2 gene fusions, ivosidenib (Tibsovo) targets IDH1 mutations, and zanidatamab (Ziihera) targets HER2-positive tumors. These are usually used after first treatment stops working, and they can shrink or control the cancer for a period, though not cure it. Relieving bile blockage is a treatment in its own right. A stent (a small plastic or metal tube) placed during ERCP, or a drainage tube placed through the skin, lets bile flow again, easing jaundice and itching and lowering the risk of infection. Radiation, treatments delivered directly to liver tumors, and clinical trials are other options, and palliative care for pain, appetite and itching is useful at any stage, not only at the end of life.

What to Expect

The course depends heavily on the cancer's location, its stage at diagnosis and whether surgery is possible. Even after a successful operation the cancer can come back, so follow-up involves regular scans and blood tests, often including CA 19-9. For people with advanced disease, treatment generally aims to control the cancer and keep life as full as possible rather than to cure it. Survival statistics are sobering, but they are based on people diagnosed several years ago, before current immunotherapy and targeted drugs were available, and they cannot predict any one person's outcome. Daily life is often shaped by the bile ducts as much as by the cancer itself. Many people live with a stent or an external drain, and a stent may need replacing every few months, or sooner if it clogs. Fatigue, reduced appetite, weight loss and difficulty digesting fatty food are common, and a dietitian can help maintain strength. Chemotherapy is usually given in cycles at an infusion center, with blood tests before each one. Because this cancer is uncommon, care at a center that treats many bile duct cancers and is reviewed by a team of surgeons, cancer specialists and gastroenterologists can open up options, including clinical trials. Bringing palliative care in early, talking openly with family about goals and making advance plans can help people keep control of decisions as the illness changes.

When to Seek Help

See a doctor right away for yellowing of the skin or eyes. Jaundice usually has a cause other than cancer, such as gallstones or hepatitis, but it always needs prompt evaluation. Book a visit for persistent itching, dark urine, pale or greasy stools, unexplained weight loss or ongoing pain below the right ribs. People with primary sclerosing cholangitis should ask their specialist about the monitoring plan. If you already have bile duct cancer or a stent or drain, contact your care team right away, day or night, for fever or chills, returning or deepening jaundice, or a drain that stops draining. These can signal a blocked stent or an infection of the bile ducts (cholangitis), which can become serious quickly and usually needs antibiotics and a procedure to restore drainage. If fever or chills come with confusion, fainting or light-headedness, very fast breathing or heartbeat, or feeling severely unwell, call 911 or go to an emergency room, since these can be signs of sepsis, a life-threatening response to infection. During immunotherapy, contact the treatment team promptly about new diarrhea, a new cough or shortness of breath, or other new symptoms, since these can be early signs of immune-related inflammation.

Questions to Ask Your Doctor

  1. 1.Where in the bile ducts is my cancer, and can surgery remove all of it?
  2. 2.Has my tumor had molecular testing, and do any results open up targeted treatments or clinical trials?
  3. 3.What are the goals of the treatment you recommend, and what side effects should I expect to report right away?
  4. 4.If I have a stent or drain, how will we watch for blockage or infection, and whom do I call after hours?
  5. 5.Would it help to get an opinion from a center that treats many bile duct cancers, and when should palliative care join my team?

Last reviewed • Oct 2026

Educational content, not medical advice.